A-DP2

A-DP2 is an experimental **human serum albumin-doxorubicin conjugate** designed as a comparator within an MMP-responsive anticancer drug-delivery program. It consists of a maleimide-linked doxorubicin peptide derivative covalently attached at cysteine-34 of human serum albumin. Its linker contains the octapeptide Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, which was reported not to be cleaved by activated matrix metalloproteinase-2 or matrix metalloproteinase-9; consequently, it lacks the intended MMP-triggered release behavior observed for the related conjugate A-DP1. The conjugated doxorubicin payload has the established cytotoxic pharmacology of DNA intercalation and topoisomerase II inhibition, but no specific antitumor efficacy result for A-DP2 was reported in the cited study. ([europepmc.org](https://europepmc.org/abstract/MED/11454467))